Innate Pharma S.A.
IPHA
$2.07
$0.041.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 9.12% | 16.45% | -163.39% | -168.69% | -1,525.37% |
| Total Depreciation and Amortization | -34.72% | -39.99% | -41.66% | -40.49% | -69.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6,211.28% | 5,699.09% | 333.67% | 342.50% | -96.46% |
| Change in Net Operating Assets | -156.20% | -151.66% | 191.73% | 193.58% | 241.93% |
| Cash from Operations | -1,182.35% | -1,095.06% | 53.38% | 52.44% | 126.19% |
| Capital Expenditure | 78.40% | 80.14% | -154.87% | -159.39% | 9.45% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 510.25% | 461.03% | -60.07% | -59.26% | 1,806.41% |
| Cash from Investing | 688.98% | 625.34% | -60.79% | -60.00% | 474.61% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -0.81% | -0.81% | -488.79% | -488.79% | -177.29% |
| Issuance of Common Stock | 15,955.91% | 15,955.91% | 5,931.91% | 5,931.91% | -73.28% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 355.28% | 334.69% | -131.14% | -135.83% | -243.42% |
| Foreign Exchange rate Adjustments | 519.31% | 485.45% | -290.49% | -294.16% | -275.29% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2,072.64% | -1,897.07% | -339.84% | -348.69% | 95.25% |